Skip to main content
Method to overcome treatment resistant cancer by rescuing STING signaling

Method to overcome treatment resistant cancer by rescuing STING signaling

Unmet Need Among types of brain cancer, glioblastoma (GBM) is the most common and the most devastating. Over 8000 patients are diagnosed annually in the United States, accounting for half of all primary malignant brain…

Read More

A tool to facilitate high affinity binding between beta-Arrestin and GPCR

A tool to facilitate high affinity binding between beta-Arrestin and GPCR

Unmet Need Beta-arrestins are a highly conserved family of cytosolic adaptor proteins that contribute to a multitude of physiological functions through a canonical interaction with various G protein-coupled receptors (GPCRs). Through agonist binding to GPCRs,…

Read More

A new method for treating chronic pain including cancer pain

A new method for treating chronic pain including cancer pain

Unmet Need According to the CDC, chronic pain has been linked to numerous physical and mental conditions and contributes to high health care costs and low productivity. Available studies estimate that the prevalence of chronic…

Read More

Beta-arrestin inhibition to prevent S1P1 internalization as a treatment for intracranial diseases

Beta-arrestin inhibition to prevent S1P1 internalization as a treatment for intracranial diseases

Value Proposition Glioblastomas (GBMs) are among the most common and deadly malignant brain tumors with a mean survival time of approximately 14-15 months following diagnosis. Current treatments for GBMs include surgery, radiation, and chemotherapy, however,…

Read More

Have Questions?

Please contact us or subscribe for more opportunities

Stay in Touch with Us